Plasma dopamine-beta-hydroxylase activity and thyroid suppressibility in Graves' disease.
Plasma dopamine-beta-hydroxylase (DBH) activity, serum T4, T3, T3U, and the 24-hr thyroid uptake before triiodothyronine suppression testing were studied in 34 patients with treated Graves' disease. Although all of them were in the euthyroid state, there was a statistically significant difference in presuppression plasma DBH activity between those patients who showed suppression of their RAI uptake with triidothyronine and those who did not. This suggests a relationship between plasma DBH activity and thyroid suppressibility.
D004299:Dopamine beta-Hydroxylase / Q000097:blood*; D006111:Graves Disease / Q000201:enzymology / Q000503:physiopathology*; D006801:Humans; D007455:Iodine / Q000378:metabolism; D013961:Thyroid Gland / Q000503:physiopathology*; D013974:Thyroxine / Q000097:blood; D014284:Triiodothyronine / Q000097:blood
D014284:Triiodothyronine; D007455:Iodine; D004299:Dopamine beta-Hydroxylase; D013974:Thyroxine